Both Pfizer And GSK RSV Vaccines Set For Approval – But Could Next Readouts Give One The Edge?
Longer Term Data Ready Soon
The two frontrunners look set to gain US FDA approval, but will need more robust long-term data to convince frontline physicians and payers of benefits to at-risk individuals.
You may also be interested in...
Phase III Results Show Moderna Could Challenge In Blockbuster RSV Vaccine Market
Moderna has moved fast to catch up with GSK and Pfizer, but will still be up to a year behind in reaching the market in the burgeoning RSV market.
Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy
Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.
Pharming’s Portfolio Grows As Ultra-Rare Disease Drug Joenja Is Approved
The first ever approval for ultra-rare immunodeficiency disease APDS gives Pharming its second product on the market but patient diagnosis will be a major challenge.